recurrent cervical carcinoma
Showing 1 - 25 of 32
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma Trial in United States (Laboratory
Active, not recruiting
- Cervical Adenocarcinoma
- +5 more
- Laboratory Biomarker Analysis
- Nivolumab
-
Birmingham, Alabama
- +336 more
Jan 28, 2023
Human Papilloma Virus Circulating Tumor DNA in Cervical Cancer
Recruiting
- Cervical Adenosquamous Carcinoma
- +26 more
- Biospecimen Collection
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,
Terminated
- Recurrent Gynecological Cancer
- +10 more
- Durvalumab
- +2 more
-
Boston, MassachusettsMartin King
Oct 4, 2022
MRI and PET Imaging in Predicting Treatment Response in Stage
Active, not recruiting
- Cervical Adenocarcinoma
- +12 more
- Computed Tomography
- +5 more
-
Miami, Florida
- +5 more
Oct 4, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston
Recruiting
- Malignant Female Reproductive System Neoplasm
- +24 more
- Quality-of-Life Assessment
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 6, 2022
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting
- Immune Checkpoint Inhibitors
- +9 more
- Radiotherapy for targeted lesions and PD-1 antibody
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus
Recruiting
- Recurrent Cervical Carcinoma
- +9 more
- Tislelizumab plus radiotherapy
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1
Recruiting
- Targeted Therapy
- +6 more
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1
Completed
- Recurrent Cervical Carcinoma
- +4 more
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)
Completed
- Recurrent Cervical Carcinoma
- +5 more
- Chemotherapy plus apatinib
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA
Active, not recruiting
- Human Papillomavirus-16 Positive
- +20 more
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- Durvalumab
-
Houston, TexasM D Anderson Cancer Center
Feb 11, 2022
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in
Completed
- Cervical Adenocarcinoma
- +6 more
- Atezolizumab
- +2 more
-
Los Angeles, California
- +21 more
Apr 20, 2021
Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and
Recruiting
- Recurrent Cervical Carcinoma
- +6 more
- Combination of nimotuzumab and radiotherapy
-
Beijing, Beijing, ChinaLei Li
Dec 18, 2020
Chemo, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma Trial in Beijing (Drug therapy)
Recruiting
- Chemotherapy
- +6 more
- Drug therapy
-
Beijing, Beijing, ChinaLei Li
Nov 15, 2020
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in
Completed
- Cervical Adenocarcinoma
- +3 more
- Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
- Laboratory Biomarker Analysis
-
Birmingham, Alabama
- +23 more
Aug 21, 2020
Cervical Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Bronx (Palliative Therapy, Palliative Therapy +
Completed
- Cervical Carcinoma
- +9 more
- Palliative Therapy
- Palliative Therapy + idiographic
-
Bronx, New YorkAlbert Einstein College of Medicine
Sep 13, 2019
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma Trial in United States (biological,
Completed
- Cervical Adenocarcinoma
- +7 more
- Filgrastim
- +4 more
-
Orange, California
- +77 more
Aug 6, 2019
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in
Completed
- Cervical Adenocarcinoma
- +4 more
- Cisplatin
- +3 more
-
Los Angeles, California
- +24 more
Jul 17, 2019
Advanced Malignant Tumor, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma Trial in Scottsdale, Rochester (Laboratory
Completed
- Advanced Malignant Neoplasm
- +31 more
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, Arizona
- +1 more
Jun 5, 2019
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in
Completed
- Cervical Adenocarcinoma
- +4 more
- Brivanib Alaninate
- Laboratory Biomarker Analysis
-
Phoenix, Arizona
- +42 more
Mar 8, 2019
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma Trial in United States (Paclitaxel
Completed
- Cervical Adenocarcinoma
- +4 more
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Laboratory Biomarker Analysis
-
Aurora, Colorado
- +25 more
Dec 17, 2018
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma Trial in Philadelphia (Cisplatin,
Completed
- Cervical Adenocarcinoma
- +4 more
- Cisplatin
- +5 more
-
Philadelphia, PennsylvaniaGynecologic Oncology Group
Sep 18, 2018